Publications
Detailed Information
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Michael, Michael | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Hamid, Oday | - |
dc.contributor.author | Thornton, Donald | - |
dc.contributor.author | Tate, Sonya C. | - |
dc.contributor.author | Raddad, Eyas | - |
dc.contributor.author | Tie, Jeanne | - |
dc.date.accessioned | 2021-01-31T12:04:53Z | - |
dc.date.available | 2021-01-31T12:04:53Z | - |
dc.date.created | 2018-09-04 | - |
dc.date.issued | 2017-08 | - |
dc.identifier.citation | Targeted Oncology, Vol.12 No.4, pp.463-474 | - |
dc.identifier.issn | 1776-2596 | - |
dc.identifier.other | 50277 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173259 | - |
dc.description.abstract | Background We report here a phase 1 study of LY2874455, a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor. Objective The primary objective was to determine the recommended phase 2 dosing (RP2D). Secondary objectives included determining toxicity, antitumor activity, pharmacokinetics (PK), and pharmacodynamic (PD) properties of LY2874455. Patients and Methods This study comprised two parts: (a) dose escalation with 3 + 3 cohorts in patients with solid tumors and (b) dose-expansion cohorts in patients with gastric cancer (GC) and non-small cell lung cancer (NSCLC). Part A: 36 patients in 11 dose cohorts ranging from 2 to 24 mg twice daily (BID). RP2D was 16 mg BID. Part B: GC cohort, 29 patients, NSCLC cohort, 27 patients, all treated at the RP2D. Results LY2874455 was slowly absorbed and generally showed linear PK. The effective half-life was similar to 12 h. PD properties of LY2874455 occurred at doses >= 10 mg by increases in serum phosphorus. Phosphate binders were administered to control serum phosphorus. LY2874455 was generally well tolerated; most toxicities were grade 1 or 2; most frequent were hyperphosphatemia, diarrhea, and stomatitis. Efficacy: part A: 24 patients evaluable: 1 patient in the 14-mg BID cohort with GC had a partial response (PR); 14 patients had stable disease (SD); part B: NSCLC cohort: 11 of 12 evaluable patients had SD; GC cohort: 15 patients evaluable: 1 patient with PR; 12 patients with SD. Conclusions LY2874455 has an RP2D of 16 mg BID and demonstrated good tolerability and activity in solid-organ cancer patients. The role of FGFR inhibition on tumor growth in patients requires further study. (NCT01212107). | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1007/s11523-017-0502-9 | - |
dc.citation.journaltitle | Targeted Oncology | - |
dc.identifier.wosid | 000406317200005 | - |
dc.identifier.scopusid | 2-s2.0-85020281955 | - |
dc.citation.endpage | 474 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 463 | - |
dc.citation.volume | 12 | - |
dc.identifier.sci | 000406317200005 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTORS | - |
dc.subject.keywordPlus | ADVANCED SOLID TUMORS | - |
dc.subject.keywordPlus | GASTRIC-CANCER | - |
dc.subject.keywordPlus | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject.keywordPlus | DOSE-ESCALATION | - |
dc.subject.keywordPlus | AMPLIFICATION | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | MUTATIONS | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.